Heart Breaking Harford's Economic conditions "Hartford and America" by SchiffGold

Hartford and America: Suffering the "Consequences of Political Malfeasance"
October 4, 2017  by SchiffGold
Peter Schiff, the gold and silver guru writes about the worsening economic conditions of Hartford, the capital of the state of Connecticut.
Hartford was going through budget and spending crisis for more than a decade, ultimately reaching a level where nations two rating agencies S&P and Moody's downgrading Hartford Economic condition to a Junk status, and the city might default on its obligations may further lead to bankruptcy as early as November. Schiff's piece came up just two days ago, but several days earlier, the WSJ published a report on the ratings on Sept28

WSJ: Hartford Downgraded Further Into Junk Status  
Moves by S&P and Moody’s cites increased likelihood of default as early as November
By Joseph De Avila

Updated Sept. 26, 2017 11:33 p.m. ET

Two credit-ratings firms on Tuesday downgraded the city of Hartford further into junk status, citing an increased likelihood of default as early as November.

Schiff digs further into how did the city of Hartford reached this stage, further expanding the understanding that not only city of Hartford, but the once wealthiest state of CT, the state as a whole is in trouble too, owning 3.5Billion debt and close to 70Billion in pension liabilities etc?... It does not look for the city or state economically and otherwise, what about other cities and states nationwide, read the piece here.....LINK

New Haven Neighborhood

CURE Cookout Draws Biotech Crowd to Branford
Back by popular demand,

the CURE summer biotech cookout was held again this year at the Owenego Inn in Branford.

More than 175 employees and friends of CURE member organizations registered for the July 17 event, playing the DNA Game, sampling the hot and cold buffet, and networking in the sunshine along the beautiful Connecticut shoreline.
For the full story

CURE Member News Digest
454 Life Sciences reports Neanderthal genome sequencing
Achillion CEO cites Q2 progress
Alexion announces new patent
Applied Spine device implanted in local man
Bayer HealthCare cites Nexavar® progress
Boehringer Ingelheim reports Aptivus® approval
Bristol-Myers Squibb offers ReSEARCH program to students
Cantor Colburn newsletter reviews trademark case
Connecticut Innovations named to top 100 list
CuraGen pleased with Q2 progress
Danbury Hospital heart center offers newest stents
GlaxoSmithKline reports results on HuMax-CD20®
Hartford Hospital welcomes electrophysiology head
HistoRx names diagnostic operations head
Ipsogen wins CE marking for JAK2 test
Johnson & Johnson cites VisiCare Institute™ role at Olympics
MannKind to host plant dedication in Danbury
NanoViricides sees efficacy for its EKC-Cide™ for eyes
Neurogen focuses of Phase 2 drug
Pfizer promotes Cerenia™ drug for dogs
PhRMA dreports on mental illness drugs
Purdue Pharma unveils tookkit for pain management
Quinnipiac University to offer online OT courses
Rib-X names George Milne executive chairman
Triumvirate Environmental acquires Enviro-Safe branches
UConn researchers report in nanotechnology publication
Vion to test Cloretazine® with Dutch group
Yale identifies West Nile genes
For the full story

Hartford Voices on Education Project: ConnCAN news!

Donald and Matthew spent their summer working on a documentary film as part of the Hartford Voices on Education Project. Do you want to know what they discovered? You'll have to come to the FREE screening Wadsworth Athenaeum 600 Main Street, Hartford, CT Wednesday, August 20, 6-8pm The Hartford Voices on Education Project is a collaborative effort between ConnCAN and the North Hartford Strategic Network. Through this intensive six-week filmmaking and community storytelling initiative, Hartford teens were given the opportunity to learn valuable video production skills and to engage with community members around how to improve public education in their city. Learn more and watch the trailer.

If you no longer wish to receive these emails, please reply to this message with "Unsubscribe" in the subject line or simply click on the following link: Unsubscribe

ConnCAN 85 Willow St New Haven, CT 06511 Read the VerticalResponse marketing policy.

Deadly Hit and Run, InHuman bystanders of Hartford?

It is absolutely terrifying and disturbing to see this hit and run accident in Hartford, the cars keep rolling, people seems to walk around as though there is nothing to be concerned about?, despite this hartford man knocked out by a deadly bastard who took off the road without any remorse or concern to the human he had hit on the middle of the road?.



http://www.courant.com/

What is Happening in New Haven-CT?

Well, Obama won the CT primary, good job CT. Here are some top of the line website in Connecticut which supports Obama and sites with latest news about Obama!


http://ctobama.ning.com/
http://www.obamact.blogspot.com/
&
http://www.ctnewsjunkie.com/
http://www.blognetnews.com/connecticut/

CURE & YALE University: Yale BioHaven Enterprenurship

Tuesday, February 12, 2008 Rib-X Pharmaceuticals, Inc. Followed by networking, refreshments & wine bar Rib-X Pharmaceuticals, Inc. is focused on the design and development of novel small-molecule antibiotics for the treatment of antibiotic-resistant infections in hospital and community settings. Since its inception in 2001, Rib-X has established a portfolio of development and discovery-stage compounds that address various segments in the diverse antibiotic marketplace, including RX-3341, a broad spectrum quinolone antibiotic which will soon enter Phase 3 studies as an IV agent and RX-1741, an oxazolidinone antibiotic now in two Phase 2 studies as an oral agent. Many classical antibiotics work by inhibiting the function of the ribosome. A key competitive advantage for Rib-X is its proprietary access to the high-resolution crystal structure of the ribosome, a molecule which is essential for the viability of all bacterial pathogens and the target of numerous valuable antibiotics. Rib-X's research goal is to use chemical and physical information from the three-dimensional structure of the ribosome to design proprietary classes of antibacterial agents that have activity against newly emerging multiple antibiotic-resistant microorganisms. Structural and computational data about how ligands block the function of this complex molecular machine are being used to prime parallel lead optimization programs focused on new chemistry ideas about the multiple binding domains or drug targets within the ribosome. The scope of the Rib-X structure based design process will enable the Company to fully exploit the chemistry of the ribosome and build a pipeline of diverse products and as a result a sustainable franchise. Rib-X raised $50 million in a Series C Preferred Stock financing announced in June of 2006. The round was led by existing investor Warburg Pincus, the global private equity investment firm. That round of financing brought the total amount raised by the company to $123 million. Speakers Susan Froshauer, Ph.D. President & Chief Executive Officer, Rib-X Pharmaceuticals, Inc. Erin Duffy, Ph.D. Vice President, Structure Based Drug Design, Rib-X Pharmaceuticals, Inc. Tuesday, February 12, 2008 3:30 P.M. Registration 4:00 P.M. Seminar 5:00 P.M. Networking, Refreshments & Wine Bar Location The Anlyan Center auditorium, Yale Medical School. Directions & Parking: http://info.med.yale.edu/maps/cab.html RSVP Registration is free, but please RSVP in advance. E-mail to biohaven@yale.edu or call the Yale OCR main number: 203-785-6209. Mark Your Calendar The next seminar in the series, on March 19, 2008, features Optherion, Inc. Download a brochure of the complete 2007-2008 series here. Lead sponsors: Wiggin and Dana and PricewaterhouseCoopers. Also sponsored by Elm Street Ventures. Presented by CURE and the Yale Office of Cooperative Research. Additional support from the Yale Entrepreneurial Society and the Yale Biotechnology & Pharmaceutical Society. Published by Connecticut United for Research Excellence Copyright © 2008 Connecticut United for Research Excellence. All rights reserved. Visit CURE at http://curenet.org and BioBus Educational Programs at http://ctbiobus.org TELL A FRIEND

Powered by IMN™ this e-mail was sent to drmuni From Connecticut United for Research Excellence, 300 George Street, New Haven, CT 06511 USA

STEM CELL IN CONNECTICUT-Uconn Health Center, THE CENTER OF STEM CELL RESEARCH

CONNECTICUT HEALTH CENTER, FARMINGTON & IT'S TOP CLASS RESEARCH!

Medicine
Suddenly, Connecticut Is Stem Cell Central

IN his laboratory here at the University of Connecticut Health Center, Dr. David W. Rowe looked at two X-rays that appeared too good to be true. The first showed a mouse that had part of a tibia removed to simulate an injury so severe as to require amputation. In the next, the mouse’s leg had regrown fully